Tefibazumab, formerly known as INH-H2002, represents a novel therapeutic approach targeting complement factor H, specifically its ability to attach with C5. This protein is engineered to inhibit the formation of the C5b-9 membrane attack complex, a key driver of tissue damage in various ailments. Ea